Literature DB >> 9730338

Improved imaging of the spinal cord in multiple sclerosis using three-dimensional fast spin echo.

V L Stevenson1, I F Moseley, C C Phatouros, D MacManus, A J Thompson, D H Miller.   

Abstract

We report assessment of a new three-dimensional fast spin echo (3D FSE) sequence in ten patients with clinically definite multiple sclerosis, comparing it with standard 2D FSE, and in ten normal controls. We saw 29 focal lesions on the 2D images and 53 on the 3D FSE images (P = 0.05); none were seen in controls. Lesion length was significantly smaller on the 3D FSE than on to the 2D FSE images (3D: 1.36; 2D 2.0; P = 0.03). This may relate in part to separation into several lesions on the 3D images of confluent abnormal signal seen on 2D and in part to detection of small lesions missed by the thicker 2D FSE slices (3 mm compared to 1.5 mm). The 3D FSE sequence looks promising in improving spinal cord imaging.

Entities:  

Mesh:

Year:  1998        PMID: 9730338     DOI: 10.1007/s002340050614

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  3 in total

1.  Putaminal alteration in multiple sclerosis patients with spinal cord lesions.

Authors:  Hilga Zimmermann; Hans O Rolfsnes; Swantje Montag; Janine Wilting; Amgad Droby; Eva Reuter; Joachim Gawehn; Frauke Zipp; Adriane Gröger
Journal:  J Neural Transm (Vienna)       Date:  2015-05-14       Impact factor: 3.575

2.  Magnetization-transfer histogram analysis of the cervical cord in patients with multiple sclerosis.

Authors:  M Bozzali; M A Rocca; G Iannucci; C Pereira; G Comi; M Filippi
Journal:  AJNR Am J Neuroradiol       Date:  1999 Nov-Dec       Impact factor: 3.825

3.  Relative contributions of brain and cervical cord pathology to multiple sclerosis disability: a study with magnetisation transfer ratio histogram analysis.

Authors:  M Rovaris; M Bozzali; G Santuccio; G Iannucci; M P Sormani; B Colombo; G Comi; M Filippi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-12       Impact factor: 10.154

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.